Trabectedin and the L-Sarcomas: A Decade-Long Odyssey
Mené sur 518 patients atteints d'un léiomyosarcome ou d'un liposarcome de stade avancé en échec thérapeutique, cet essai de phase III compare l'efficacité, du point de vue de la survie globale, et la toxicité de la trabectédine et de la dacarbazine
Soft tissue sarcomas (STS) are a complex, heterogeneous group of more than 50 neoplasms of mesenchymal origin. According to the American Cancer Society, in 2015, approximately 11,930 patients in the United States will be diagnosed with STS and nearly 4,870 will die as a result of the disease. In the metastatic setting, cytotoxic chemotherapy is the standard of care and is often considered palliative. In first-line treatment, chemotherapy consists of doxorubicin (with or without ifosfamide) or gemcitabine plus docetaxel. Second-line therapies can include either dacarbazine or pazopanib. On the basis of data from the European Organisation for the Research and Treatment of Cancer, an active regimen in the second-line setting is one in which 40% of patients are progression free at 12 weeks. So, the bar to identify a successful second-line regimen in patients with metastatic STS has been set very low.